Media Contact
-
Boehringer Ingelheim GmbH
Dr Reinhard Malin
CD Communications
55216 Ingelheim am Rhein
Germany
Press Conferences
19th Great Wall International Congress of Cardiology
Disclaimer
The content of the website has been cleared by Boehringer Ingelheim GmbH in compliance with the legal provisions applicable for German companies. Such provisions vary from country to country and can have an impact on the information we can provide to you.
Thus, please contact us directly in case further information is requested which takes into account the framework in your home country.
Contact
-
23 - 26 October 2008
The ONTARGET® Trial Programme - Implications for Asia Pacific
Media Event: The results and implications of the Landmark ONTARGET® Trial Programme with a specific focus on cardiovascular care in Asia-Pacific. 16:00 - 18:40 hrs (CST) / 10:00 - 12:40 (CEST) Venue: Beijing, China Webcast on demand: The ONTARGET® Trial Programme: Implications for Asian-Pacific (Preliminary english track version - full version available soon). 
Congress Overview
News & Information
Background information for medical media outside the US only
-
News Releases
- 23.10.2008Telmisartan (Micardis®) as effective as ramipril but with better long-term tolerability in high-risk cardiovascular Asian patients
- 23.10.2008News Release (Mandarin)
- English:
- Backgrounder: Cardiovascular Disease - PDF (179 KB)
- Backgrounder: MICARDIS® - PDF (115 KB)
- Backgrounder: ONTARGET® - PDF (419 KB)
- Backgrounder: TRANSCEND® - PDF (380 KB)
Mandarin:- Backgrounder: Cardiovascular Disease - PDF (343 KB)
- Backgrounder: MICARDIS® - PDF (260 KB)
- Backgrounder: ONTARGET® - PDF (268 KB)
- Backgrounder: TRANSCEND® - PDF (663 KB)
- English:
- Glossary: Key Terms - PDF (93 KB)
Mandarin:- Glossary: Key Terms - PDF (186 KB)
Speakers
Speakers
Background information for medical media outside the US only
Professor Dans received his medical degree and fellowship in cardiology from the University of the Philippines. He currently serves as Chief of the Adult and Medical Research Unit and Chairman of the Medical Research Council of the Philippine General Hospital.
Videos: Answering the key questions
- Why is the aspect of tolerability especially important in treating Asian patients? (FLV / 0:34 min)
- How could ACE-intolerant patients be protected from cardiovascular events before TRANSCEND? (FLV / 0:38 min)
- What do the results from ONTARGET and TRANSCEND mean for Asian patients? (FLV / 0:59 min)
- What did ONTARGET show with respect to tolerability of ramipril and telmisartan in Asian patients? (FLV / 1:02 min)
- How do you evaluate the safety and tolerability of telmisartan? (FLV / 0:28 min)
Hu Dayi, MD, FACC, FESC, is a renowned expert in the field of cardiology. He is chief of the Heart Centre at Peking University's People's Hospital; director Clinical Research Institute, School of Public Health, Shanghai Fudan University; academician of International EurAsian Academy of Sciences.
Professor Liu is president of the World Hypertension League and the Chinese Hypertension League. She is also director of Clinical Trials and the Research Centre for the Chinese Hypertension League in Beijing, China.
Videos: Answering the key questions
- English
- What is the size of the cardiovascular disease problem in Asia and China? (FLV / 1:08 min)
- How is this problem predicted to grow in the future? (FLV / 0:25 min)
- Are doctors in China and Asia currently well prepared for the cardiovascular disease epidemic? (FLV / 0:26 min)
- What do the results of the ONTARGET Trial programme mean for doctors in Asia and China? (FLV / 0:33 min)
- Do you expect these results to impact national treatment guidelines in the region and China? (FLV / 0:25 min)
- Mandarin
- What is the size of the cardiovascular disease problem in Asia and China? (FLV / 1:03 min)
- How is this problem predicted to grow in the future? (FLV / 0:13 min)
- Are doctors in China and Asia currently well prepared for the cardiovascular disease epidemic? (FLV / 0:25 min)
- What do the results of the ONTARGET Trial programme mean for doctors in Asia and China? (FLV / 1:34 min)
- Do you expect these results to impact national treatment guidelines in the region and China? (FLV / 0:26 min)
Slide sets
- English
- Mandarin
Jeffrey L. Probstfield, MD graduated from Pacific Lutheran University and the University Of Washington School Of Medicine. In May 1995 he founded the Clinical Trials Service Unit in the Division of Cardiology at the University of Washington.
Videos: Answering the key questions
- English
- What do the results of TRANSCEND mean for physicians treating high risk cardiovascular patients? (FLV / 0:31 min)
- Would you expect to see the same results for other ARBs? (FLV / 1:08 min)
- What can we learn from ONTARGET and TRANSCEND? (FLV / 1:05 min)
- Why did TRANSCEND reach the hope, but not the primary endpoint? (FLV / 1:32 min)
- In the face of these results - would you treat a patient with telmisartan? (FLV / 0:23 min)
Slide sets
- English
- Mandarin
Images
Images & Videos
More images in the Boehringer Ingelheim media pool
-
B-Roll Interviews
Watch the B-Roll interviews from the 19th Great Wall International Conference of Cardiology in Beijing from 22nd and 23rd October 2008.
-
Prof. Antonio Miguel Dans
Department of Medicine, University of the Philippines College of Medicine
-
Prof. Dayi Hu
Chief of the Heart Centre, Peking University's People's Hospital China
-
Prof. Lisheng Liu
Fu Wai Hospital, Chinese Academy of Medical Sciences China
-
Prof. Jeffrey Probstfield
Co-Director Research Education Core and Director KL2 Program, University of Washington, U.S.A.